CJC-1295 with DAC (Drug Affinity Complex) is a synthetic analogue of growth hormone releasing hormone (GHRH), engineered to provide a significantly extended plasma half-life compared to native GHRH. The DAC technology works by enabling covalent binding to serum albumin, prolonging the peptide’s active duration from minutes to approximately 6–8 days. This makes CJC-1295 with DAC a valuable tool in longitudinal growth hormone research, where sustained GH and IGF-1 elevation is required without repeated dosing intervals.
In research settings, CJC-1295 with DAC has been studied for its ability to stimulate pulsatile growth hormone secretion from the anterior pituitary gland, with downstream effects on insulin-like growth factor 1 (IGF-1) production. It is of particular interest in studies relating to growth hormone deficiency models, metabolic function, body composition, and anabolic signalling pathways.
Each vial contains 2mg of CJC-1295 with DAC as a lyophilised powder, with a purity of >98% as verified by HPLC analysis. Molecular formula: C₁₆₅H₂₆₉N₄₇O₄₆; Molecular weight: 3647.1 g/mol; CAS number: 863288-34-0. Store lyophilised peptide at -20°C, protected from light and moisture. Once reconstituted, store at 4°C and use within 28 days.
Molecular Formula
C₁₆₅H₂₆₉N₄₇O₄₆
Molecular Weight
3647.1 g/mol
Purity
>98%
CAS Number
863288-34-0
Form
Lyophilised Powder
Research Applications
Growth hormone secretion studies, IGF-1 regulation research, metabolic function research, body composition studies, growth hormone deficiency models, anabolic signalling pathway research
For research purposes only. Not for human use.
Reviews
There are no reviews yet.